For personal use only

pro medicus

OUR SUPPORT. YOUR SUCCESS.

FY26 Full Year Results

August 2026

Pro Medicus (ASX:PME) | Leaders in Enterprise Imaging/Radiology Information Systems

GROUP HQ
Melbourne, AUS

EU HQ/R&D
Berlin, Germany

North American HQ
San Diego, CA USA

For personal use only

Table of Contents

- **FY26 Highlights** 4
- **Financials** 6
- **Contract Wins** 14
- **Contract Renewals** 21
- **Implementations** 23
- **Investments & Partnerships** 28
- **AI Progress** 31
- **Products** 36
- **Clinical Outcomes** 52
- **Growth Strategy** 54
- **RSNA 2025** 61
- **Summary** 65

FY26 Full Year Results | Year ended 30 June 2026 | A$ unless otherwise stated | Page references are slide numbers

For personal use only

For personal use only

FY26 Highlights

FY26 Highlights

For personal use only

- **Financials** – Underlying Revenue +28%[1], Underlying EBIT +31%[2], Underlying NPAT +33%[2], Cash Conversion 91%, Cash & Other Financial Assets $252m + 20%
- **Contract Wins** – 1 Europe, 9 US contracts signed worth total of $407m
- **Renewals** – Renewed 6 out of 6 contracts on long term, 5-year extensions
- **Implementations** – On or ahead of schedule
- **Cardiology** – gaining traction UC Health Colorado, Vancouver Clinic & Others
- **New Products** – Digital pathology and AI optimized Reporting module
- **Investments** – 4DX and EIQ agreements
- **AI** – Breast cancer detection pending FDA clearance
- **Strong Pipeline** – Increased number of opportunities across all market segments

(1) Constant currency; (2) Underlying excludes FX and Fair value gains on investments

For personal use only

Financials

For personal use only

Results FY26 Financial Performance

Revenue	Underlying EBIT	Underlying EBIT Margin	Underlying NPAT
$261.7M	$196.1M	74.9%	$144.7M
up 22.9%	up 24.4%	up 0.9pt	up 24.1%

Group earnings summary

A$m	FY26	FY25	Change	%
Revenue	261.7	213.0	48.7	22.9%
Underlying EBIT	196.1	157.7	38.4	24.4%
Underlying EBIT margin	*74.9%*	*74.0%*	*+0.9pt*	-
Underlying NPAT	144.7	116.6	28.1	24.1%
Underlying NPAT margin	*55.3%*	*54.7%*	*+0.6pt*	-
Fair value gain financial assets & interest	174.2	0.1	174.1	
Net currency gains/(losses)	(1.9)	(2.0)	0.1	
Reported profit before tax	377.5	163.3	214.2	131.2%
Income tax expense	(112.2)	(48.1)	(64.1)	
Reported NPAT	265.3	115.2	150.1	130.3%

Revenue by region

A$m	FY26	FY25	Change	%
Australia	19.0	17.7	1.3	7.3%
Europe	5.9	4.3	1.6	37.2%
North America	236.8	190.9	45.9	24.0%
Total revenue	261.7	213.0	48.7	22.9%

Underlying NPAT reconciliation

A$m	Gross	Tax	Net
Fair value gain	174.2	(52.3)	121.9
Net currency gains/losses	(1.9)	0.6	(1.3)
Total adjustments	172.3	(51.7)	120.6
Reported NPAT			265.3
Underlying NPAT			144.7

Year ended 30 June 2026 | A$ unless otherwise stated | Underlying excludes fair value movements on financial assets and net currency movements

For personal use only

Results FY26 Constant Currency

Revenue (constant currency)	Underlying EBIT (constant currency)	FX Impact on Revenue	FX Impact on EBIT
$273.5M	$206.0M	$(11.8)M	$(9.9)M
up 28.4% underlying	up 30.6% underlying	AUD/USD 0.6779 vs 0.6472	AUD/EUR 0.5812 vs 0.5950

Revenue by region (A$m)	FY26 reported	FY26 constant currency	FX impact	FY25 reported	Underlying growth $m	Underlying growth %
Australia	19.0	19.0	-	17.7	1.3	7.3%
Europe	5.9	5.8	0.1	4.3	1.5	34.9%
North America	236.8	248.7	(11.9)	190.9	57.8	30.3%
Total revenue	261.7	273.5	(11.8)	213.0	60.6	28.4%

Underlying EBIT (A$m)	FY26 reported	FY26 constant currency	FX impact	FY25 reported	Underlying growth $m	Underlying growth %
Underlying EBIT	196.1	206.0	(9.9)	157.7	48.3	30.6%

NPAT (A$m)	FY26 reported	FY26 constant currency	FX impact	FY25 reported	Underlying growth $m	Underlying growth %
Reported NPAT	265.3	275.2	(9.8)	115.2	160.0	138.8%
Underlying NPAT	144.7	154.5	(9.8)	116.6	37.9	32.5%

FY26 restated at FY25 average exchange rates | Underlying growth excludes the impact of currency movements and fair value gains/losses | A$ unless otherwise stated

Results FY26 Balance Sheet and Shareholder Returns

For personal use only

Cash Reserves	Cash and Financial Assets	NTA per Share	Total Dividend (franked)
$216.1M	$252.3M	$4.10	69.0c
up 23.8%	up 19.7%	up 81.4%	up 25.5%

Capital position

A$m	FY26	FY25	Change	%
Cash reserves	216.1	174.5	41.6	23.8%
Cash and financial assets	252.3	210.7	41.6	19.7%
Borrowings	Nil	Nil	–	–
NTA per share ($)	4.10	2.26	1.84	81.4%
Effective tax rate	*29.7%*	*29.4%*	*+0.3pt*	–

Dividends per share (franked)

Cents per share	FY26	FY25	Change	%
Interim dividend	32.0c	25.0c	+7.0c	28.0%
Final dividend	37.0c	30.0c	+7.0c	23.3%
Total dividend	69.0c	55.0c	+14.0c	25.5%

As of 30 June 2026 | A$ unless otherwise stated | Dividends are fully franked | Growth calculated on FY25 comparatives

Results FY26 - Five-year Revenue Growth

For personal use only

Revenue by revenue stream



Revenue by type, FY22 to FY26 | A$m |

For personal use only

Results FY26 Revenue Split and Forward Contracts

Revenue by geography



Forward contracts recurring revenue next five years



Revenue by geography, and forward contracts | A$m | Forward contracts of A$1.34bn over the next five years, up 41.3% in 12 months

Results FY26 Total Contract Value Signed



Total contract value by year

A$m	New	Renewals	Total
FY22	100.0	57.0	157.0
FY23	88.5	15.5	104.0
FY24	245.0	19.0	264.0
FY25	511.0	169.0	680.0
FY26	407.0	141.0	548.0
Five years	1,351.5	401.5	1,753.0

FY26 in context

Second highest year on record, behind an exceptional FY25 (includes Trinity Health).

Five year TCV signed of $1.75bn

Total contract value is minimum contracted revenue over the contract term - excludes exam volumes above contracted minimums.
FY26 comprises 10 new contracts and 6 renewals.

New contract wins and renewals signed in each financial year | A$m at contracted minimums

For personal use only

For personal use only

Financial Performance – 5 Years

Revenue Reported	FY22	FY23	FY24	FY25	FY26	CAGR (%)
Australia	14.6	15.9	16.9	17.7	19.0	5%
Europe	5.2	4.4	4.1	4.4	5.9	3%
North America	73.7	104.6	140.6	190.9	236.8	26%
Total	**93.5**	**124.9**	**161.5**	**213.0**	**261.7**	**23%**

Revenue Constant Currency	FY22	FY23	FY24	FY25	FY26	CAGR (%)
Australia	14.6	15.9	16.9	17.7	19.0	5%
Europe	5.3	6.3	4.8	4.8	5.8	2%
North America	71.7	95.1	136.1	188.0	248.7	28%
Total	**91.6**	**117.3**	**157.8**	**210.5**	**273.5**	**24%**

Underlying	FY22	FY23	FY24	FY25	FY26	CAGR (%)
EBITDA	69.7	91.8	120.8	164.9	204.2	24%
% Margin	75%	73%	75%	77%	78%	1%
EBIT	**62.4**	**83.9**	**112.3**	**157.7**	**196.1**	**26%**
% Margin	67%	67%	70%	74%	75%	2%
NPAT	**44.4**	**60.8**	**83.2**	**116.6**	**144.7**	**27%**
EPS	42.5	58.2	79.7	111.6	138.5	27%
DPS	42.4	58.1	79.5	111.4	138.3	27%

Balance Sheet	FY22	FY23	FY24	FY25	FY26	CAGR (%)
Cash & cash equivalents	63.7	30.4	60.1	107.5	146.5	18%
Term Deposits	-	60.9	63.9	67.0	69.6	NM
Total	**63.7**	**91.2**	**123.9**	**174.5**	**216.1**	**28%**

For personal use only

Contract Wins

For personal use only

Contract Wins

Total Contract Value Signed	New Contracts TCV	Renewals + Additions	Implementations
FY26: $551m	FY26: $407m	FY26 $144m: $141m + $3m	FY26: 16
10 new, 6 renewals	10 contracts - 9 US, 1 Europe	6 renewals + 1 WL addition (VISN23)	Go-lives incl. four Trinity cohorts

New contracts: $407m

UCHealth Colorado	Beth Israel Lahey Health	RANT	BayCare	University of Maryland	Five contracts
$170m / 10 years	$90m / 7 years	$44m / 5 years	$25m / 7 years	$23m / 5 years	$55m combined
Full Stack + Cardiology	Full Stack	Viewer	Archive	Viewer + Worklist	Heidelburg, Roswell Park, and Vancouver Clinic

Year ended 30 June 2026 | Total contract value at contracted minimums, A$ | Excludes transaction volumes above minimums

Contract Win – UCHealth Colorado

- A$170M 10-year deal, 2nd largest in company's history
- "Full Stack + 1" – Includes Visage 7 | Cardiology Imaging offering
- Highly respected hospital system based in Aurora Colorado
- University of Colorado Hospital – AMC Medical school and research center for Colorado University
- Went live in May 2026 – Hybrid AMC and IDN

uchealth

For personal use only

Contract Win – Heidelberg University

- A$10M – 5-year deal
- Top German medical school and teaching hospital
- Affiliated German Cancer Research Institute largest cancer research centre in Europe
- Increased PME footprint in Germany/Europe
- Went live in April 2026

For personal use only

Contract Win – Radiology Associates North Texas (RANT)

- A$44M – 5-year deal
- Private, remote reading group based in North Texas
- One of the nation's largest and most innovative private practice radiology groups
- Breast Imaging live in April 2026
- Full go live – August 2026
- Greatly strengthens PME presence in private market

RADIOLOGY ASSOCIATES OF NORTH TEXAS, P.A.

For personal use only

Contract Win – University of Maryland

For personal use only

- A$23M – 5-year deal
- Academic Medical Center
- Based in Baltimore, Maryland
- Was a key reference site for Visage competitor
- 12 hospitals across Maryland, including the University of Maryland Medical Center and world-renowned R Adams Cowley Shock-Trauma Center

UNIVERSITY of MARYLAND MEDICAL SYSTEM

Contract Win – Beth Israel Lahey Health

- A$90M – 7-year deal, 4th largest in company's history
- "Full Stack"
- Highly respected hospital system based in Boston, Massachusetts
- Academic medical centers and teaching, community and specialty hospitals
- Fourteen (14) hospitals and will include the world-renowned Dana-Farber Cancer Institute

Beth Israel Lahey Health

For personal use only

For personal use only

Contract Renewals

Contract Renewals

For personal use only

Total Contract Value Signed	New Contracts TCV	Implementations	Largest Contract
FY26: $551m	FY26: $407m	FY26: 16	FY26: $170m
10 new, 6 renewals | FY25 $680m	10 contracts | FY25 $511m	Go-lives incl. four Trinity	UCHealth Colorado, 10 years

Renewals and additions: $144m

Northwestern Medicine	MedStar Health	Allegheny Health Network	FMOL Health	The Ohio State University Wexner Medical Center / Zwanger-Pesiri Radiology	VISN 23
$37m / 5 years	$31m / 5 years	$28m / 5 years	$20m / 5 years	$16m / $9m 5 years	$2.8m Worklist module added

All renewals for 5-year period at higher per transaction fee transaction

Year ended 30 June 2026 | Total contract value at contracted minimums, A$ | Addition: $2.8M VISN 23 Worklist module

For personal use only

Implementations

Implementations

For personal use only

Total Contract Value Signed
FY26: $551m
10 new, 6 renewals | FY25 $680m

New Contracts TCV
FY26: $407m
10 contracts | FY25 $511m

Implementations
FY26: 16
Go-lives incl. four Trinity

Largest Contract
FY26: $170m
UCHealth Colorado, 10 years

Visage® 7 Go-Live Implementations: 16 go-lives

Trinity Health, BayCare	uchealth	FMOL Health	Universität Heidelberg	RSNA
16 Go-Lives completed 4 Trinity Health cohorts, BayCare	Live in 10 months Signed July 2025, Go-Live May 2026	FMOL, VISN 23 Two Cloud Migrations Moved from On-Prem	European Go Live Heidelberg University Voted 12th best hospital in the world	RSNA 2025 Busiest to date Continued progress across other –ologies, reporting and AI

Total contract value is minimum contracted revenue over the initial term and excludes transaction volumes above contracted minimums. FY26 comprises 16 go-lives, including four Trinity Health cohorts.

Year ended 30 June 2026 | Total contract value at contracted minimums, A$ | Excludes transaction volumes above minimums

For personal use only

Implementations – Progress at 30 June 2026

Announced	Customer	Contract Value (A$)	Term	Implied Annualised (A$)	Go- Live Target	Progress	% Implemented FY26
28-Nov-24	Trinity	$330m	10 years	$33m	4Q CY25	On Schedule	75%
04-Dec-24	Lurie's Children's Hospital	$5m	7 years	$1m	3Q CY25	On Schedule	100%
16-Jan-25	University of Kentucky	$33m	9 years	$4m	4Q CY25	On Schedule	100%
04-Feb-25	BayCare	$53m	7 years	$8m	1Q CY26	On Schedule	100%
03-Mar-25	Lucid Health	$40m	7 years	$6m	3Q/4Q CY25	On Schedule	100%
08-May-25	University of Iowa	$20m	5 years	$4m	4Q CY25	On Schedule	100%
03-Jul-25	University of Colorado	$170m	10 years	$17m	2Q CY26	On Schedule	100%
08-Oct-25	University Hospital Heidelberg	$10m	5 years	$2m	2Q CY26	On Schedule	100%
17-Nov-25	Radiology Associates North Texas	$44m	5 years	$9m	1Q CY26	On Schedule	10%
24-Nov-25	The Vancouver Clinic	$13m	7 years	$2m	3Q CY26	On Schedule	0%
08-Apr-26	University of Maryland	$23m	5 years	$5m	1Q CY27	On Schedule	0%
18-May-26	Beth Israel Lahey(1)	$90m	7 years	$13m	1Q CY27	On Schedule	0%
24-Nov-25	Roswell Park Cancer Centre	$9m	7 years	$1m	2Q CY26	On Schedule	100%
01-Jun-26	TidalHealth	$16m	7 years	$2m	4Q CY26	On Schedule	0%
12-Aug-26	St Luke's Health System	$23m	7 years	$3m	1Q CY27	On Schedule	0%

(1) Multiple cohorts

For personal use only

Implementations – Trinity Health Update

- Contract signed – November 2024
- Arguably, the largest CloudPACS in the world
  - National footprint, centralized in the cloud, high availability
  - Centralized workflow platform across the entire network, enables national reading across time zones
- Phased implementation – 7 cohorts; 5 cohorts complete (87%)
  - Cohort 1 – Oct 27 2025
  - Cohort 2 – Jan 19 2026
  - Cohort 3 – Apr 13 2026
  - Cohort 4 – June 1 2026
  - Cohort 5 – July 20 2026
- Cohorts 6 and 7 – remaining 13% completed by October 2026

Trinity Health

Implementations – Competitive Advantage

For personal use only

- All implementations on or ahead of schedule
- Fast track methodology continues to deliver
- Large scale projects completed in under 1/4 to 1/5 the time of industry norm
- Delivers huge savings for client
- Free(s) PME staff for other jobs
- Reduces barrier to change
- Highly optimized hybrid model (onsite + remote)
- A key differentiator of Visage offering



For personal use only

Investments & Partnerships

Investment – 4DMedical (ASX:4DX)

- $10m investment – hybrid debt and equity
- 2-year term maturing 31 July 2027
- Coupon rate of 12.5% PA
- $20m payout if share price doubles
- Equity component if share price more than doubles (>$0.48)
- Unrealised gain ~$172m as of 30 June 2026

For personal use only

Investment – Echo iQ (ASX:EIQ)

For personal use only

- A$10m initial investment in secured unlisted convertible notes at A$1.05 per note
- Option to invest another A$10m upon Echo IQ receiving FDA clearance of EchoSolv HF
- 2-year term maturing after issue date
- Coupon rate of 12.5% PA
- Options – 0.75 unlisted options per note with A$1.35 exercise price

EchoiQ

For personal use only

AI Progress

AI in Healthcare

For personal use only

- Healthcare and AI – ideally matched
- Imaging at the vanguard of healthcare AI
- Highly regulated environment – FDA, CE, TGA
- Mission critical - zero downtime/zero errors
- AI must be imbedded in complex workflows to be used by clinicians
- AI must be trusted – can't be a black box

Visage 7 | AI

- PME/Visage ideally placed to benefit from AI
- Visage 7.0 desktop the “gate keeper” for image-based AI integration
- Visage used by ~ 11% of US market and growing
- Ability to imbed AI into core Visage 7 offering
- Capital light strategy sourcing best in breed algorithms

For personal use only

Visage 7 | AI

For personal use only

- Breast cancer detection algorithm co-developed with NYU – commercialisation pending FDA clearance
- Investment in Elucid for Cardiac CT AI
- Investments in 4DMedical and Echo IQ
- Research collaboration agreements with UCSF, Mayo, NYU and others
- Growing number of 3rd party AI integrations



For personal use only

AI – Research Leadership

Malte Westerhoff, PhD
Global Chief Technology Officer

Detlev Stalling, PhD
Head of Development

MingDe Lin, PhD
Clinical Research Manager, North America

For personal use only

Products

Visage 7 One Platform – All Imaging

For personal use only

- Single viewer for ALL images in the medical record (EHR) – Enterprise Imaging
- Radiology/Cardiology/Pathology
- Non-radiology– reflected light – hi-res photos & videos
- Same code base as Visage 7 platform
- Increases Visage value proposition
- Growth opportunities within existing contracts



Radiology · Cardiology · Digital Pathology · Breast Imaging · Teleradiology · Specialty Workflow
Ophthalmology · POCUS · Dental · Remote Reading · Non-DICOM · Visible Light · Multimedia

For personal use only

Visage® 7

SPEED | FUNCTIONALITY | SCALABILITY

For personal use only

Competition – Legacy Technology

"Compress & Send"



Pro Medicus – Solution

For personal use only

"Streaming Technology"



Driver – Massive Data Explosion

For personal use only

- Photon-Counting CT – .2 mm; 10,000+ images
- HD Breast Tomosynthesis – 6 GB+
- Digital Pathology – 10 GB+ with cystology up to 30 GB
- Optoacoustic Breast Ultrasound – 10 GB+
- Total Body PET Scan – 10 GB+
- 7T MRI – much larger than 3T



For personal use only

Driver – Radiologist Burnout – The New Epidemic

- Acute worldwide shortage of radiologists
- Reduced intake of radiology residents – fears AI would take over
- Larger datasets – more images to look at
- Work life balance post COVID – work from home mandatory part of the mix
- Many groups struggling to handle current workload, falling behind
- Groups starting to cut back on reporting contracts

For personal use only

Visage 7 CloudPACS

- Visage 7 – fully Cloud native
- Same ultrafast performance as on-premise
- Full Visage 7 functionality
- Security and scale of the cloud
- Suitable for all size implementations
- Pipeline opportunities mandating Cloud deployment
- Cloud vendor agnostic – large scale implementations in all three clouds – AWS, Azure and Google GCP
- Significant strategic advantage over competitors

For personal use only

Visage 7 Open Archive

- Same highly scalable Visage 7 platform
- Interoperable – works in complex environments
- Enables choice of modular or single vendor solutions
- Visage 7 Open Archive integral part of “Full Stack” solution
- Pipeline – most opportunities include Visage 7 Open Archive
- Key component of Visage Cloud strategy
- Transaction based model with potential upside

For personal use only

Visage 7 Workflow

- Adds to Viewer and Open Archive modules
- Based on over 30 years experience in Workflow SW
- Allows PME to offer “full stack” solution
- Integral part of Visage CloudPACS SaaS solution
- Ability to interface with broad range of AI algorithms
- Sold in majority of new contracts
- Transaction based model with potential upside

Visage 7 | Reporting

- Announced at SIIM 2026
- First implementations during 2026
- Native, ultrafast, AI optimized reporting
- Intelligent AI tools improve quality and save valuable time
    - Draft From Prior
    - Revise tools
    - Auto Impression generation
    - Error checking

For personal use only

For personal use only

Visage 7 | Cardiology Imaging

- Cloud-based Workflow and Imaging Solution for Cardiology Imaging
- Same code base as Visage 7 platform
- Ultrafast, immediate access to massive Cardiology datasets
- Native Cardiology Imaging tools
- Advanced interoperability – export measurements to Epic Cupid



Visage 7 | Digital Pathology

For personal use only

- Native support within the Visage 7 Enterprise Imaging Platform
- Fully Cloud-based (Visage 7 | CloudPACS)
- Spatial computing support via Visage Ease VP for Apple Vision Pro
- Validation of IHE Digital Pathology Profile at the 2025 IHE-Europe Connectathon

Visage 7 | Digital Pathology

For personal use only

VISAGE RIS



Visage RIS

For personal use only

- Long term (5 year) contracts with Lumus (Primary Healthcare) and I-MED, the 2 biggest radiology providers in AUS
- Upside via client organic and M&A growth
- Increased market interest – new opportunities
- PME undisputed market leader

VISAGE RIS

I-MED Network Radiology
Comprehensive care. Uncompromising quality.

Healthcare Imaging Services
Affordable | Accessible | Imaging

For personal use only

pro medicus | VISAGE IMAGING®

Clinical Outcomes

For personal use only

Delivering Clinical Outcomes

Moving the Needle

Delivering Clinical Outcomes & Proven ROI

For personal use only

Significant IT & Infrastructure Savings

Unparalleled Increase in Radiologist Efficiency

Greater Clinical Accuracy



Improved Physician Engagement

Delivers Superior Value Proposition

For personal use only

pro medicus | VISAGE IMAGING®

Growth Strategy

For personal use only

Growth Strategy

North American – TAM

For personal use only

- 690 Million exams performed per annum in the US
  - Growing by ~3% per year
  - In contrast, Visage customers are growing by ~8%
- Visage able to address 100% of TAM from a product perspective
- ~ 85% of TAM addressable from commercial perspective – “full stack”, cloud etc…
- Current market penetration is ~11% and growing
- Very large addressable runway



For personal use only

North American Pipeline



Pipeline Robust
In terms of quality and quantity of opportunities

Opportunities
Increased number of inbound RFPs

Network Effect
Further increased from recent high-profile wins in both Tier-1 academic and IDN markets

Prospects
Progressing through various stages of the cycle

Largest Footprint in AMC

- 2026/2027 Best Hospitals

(alphabetical order)

- >50% of the Best Rated U.S. Hospitals (11 out of 20) use Visage 7 for PACS

For personal use only

IDN Segment – Growing Footprint

- IDNs represent the largest segment of the market
- IDN clients across broad spectrum of opportunities from large, national, multi-state, to smaller regional
- Most recent IDN sales for more than one Visage product – many "full stack" +
- 100% cloud deployments since September 2020
- Increasing network effect in this important market segment

For personal use only

Private Market Segment

- Previously “dormant” due to increased M&A activity
- RANT (ARM) A$44M 5-year deal
- Adds to A$70M contracted in private market in FY25
- Confirms Visage platform suited to broad range of market segments
- Opens more opportunities in this market space

For personal use only

For personal use only

RSNA 2025

Visage Ease VP for Apple Vision Pro



"Underpins our belief that our technology is 18 to 24 months ahead of competitors, if not more."

For personal use only

Apple Store Event – RSNA 2025

For personal use only

Pro Medicus – RSNA 2025

For personal use only

pro medicus | VISAGE IMAGING

For personal use only

pro medicus | Visage Imaging®

Summary

Summary

For personal use only

- **Record Financials** – Underlying Revenue +28%[1], Underlying EBIT +31%[2], Underlying NPAT +33%[2], Cash Conversion 91%, Cash & Other Financial Assets $252m + 20%
- **Cloud** – Huge strategic advantage over competitors
- **Contract Wins** – Majority "full stack", 10 contracts signed worth total of A$407m
- **Renewals** – Renewed 6 out of 6 contracts on long term, 5-year extensions
- **Implementations** – All on schedule, we have proven implementation & support capability
- **Cardiology** – Gaining traction with Full stack +1 for UColorado, Vancouver Clinic, MedStar Health
- **New Products** – Visage 7 Reporting, Digital Pathology, increasing use cases for Visage Ease VP for Apple Vision Pro
- **Investments** – Broadens and deepens product offering with 4DX and EIQ agreements
- **AI** – Breast cancer detection pending FDA clearance, ideally positioned to leverage AI
- **Strong Pipeline** – Increased number of North American opportunities across all segments

(1) Constant currency; (2) Underlying excludes FX and Fair value gains on investments

For personal use only

pro medicus | VISAGE IMAGING®

Thank You